New technologies in the management of types 1 & 2 diabetes

The practice of diabetes management is currently, in many respects, at a state of satisfaction. Glucose meters have reached a level of sophistication that is largely addressing the needs of diabetics, and the same is true of insulin pumps. The main remaining product innovation opportunities in the devices sector are the development of truly noninvasive glucose metering instruments and the development of an automatic closed-loop system linking glucose metering with insulin administration, otherwise known as the “artificial pancreas”. This latter development will eventually drive significant, perhaps dramatic, growth in the devices sector but this is not likely to happen in less than 3–5 years.

In the pharmaceutical sector, a number of insulin analogs are now available that go far to satisfy the demands of diabetics. New classes of oral anti-diabetic drugs continue to be developed, but several of the older classes are still widely used.

Until the goal of managing diabetes more thoroughly and holistically is achieved by tackling the underlying genetic and immunological causal mechanisms, rate of utilization of diabetes products (and associated manufacturer sales) will be driven principaly by the increasing prevalence of both main types of diabetes, especially in the developed world, with incremental growth resulting from the introduction of improved versions of current drugs and devices. Consequently, we estimate an annual growth rate around 12% in the aggregate diabetes management market over the next eight years. Major technological and/or scientific breakthroughs could, of course, make it necessary to revise this forecast, with the most likely candidates being the more rapid approval of the artificial pancreas or unanticipated advances in cell therapy (islet cell transplant, stem cell transplant, others).

The current range of diagnosis, monitoring and treatment products on the market or in development for diabetes (types 1 & 2) are below:

  • Products Used in Diagnosis and Monitoring
    • Blood Glucose Monitoring Devices
      • Lancets
      • Blood Sampling Devices
      • Blood Glucose Monitors
      • New Developments in Glucose Testing
    • Artificial Pancreas
    • Other Testing Approaches
      • Hemoglobin A1c
        • Hemoglobin A1c Meters
        • Hemoglobin A1c Kits
    • Software Programs for Diabetes Monitoring
      • Web Software
      • Commercial Software
  • Products Used in Treatment
    • Insulin
      • Bovine and Porcine Insulin
      • Humanized Insulin
    • Insulin Delivery
      • Syringes
      • Pens
      • Injectors
      • Inhaled insulin
      • Insulin Pumps (alone and integrated with monitor in "artificial pancreas")
    • Oral Hypoglycemic Agents
      • Sulfonylureas
      • Biguanides
      • Alpha-Glucosidase Inhibitor
      • Thiazolinediones/Glitazones
      • Prandial Glucose Regulators/Meglitinides
      • Incretin Mimetics/GLP-1 Analogs
      • DPP-4 Inhibitors
      • Amylin Mimetic
      • SGLT2 Inhibitors
      • Other
    • Cell Therapies

(Specific products in use and the products/technologies under development are detailed in Diabetes Report #D510.)

From "Diabetes Management: Products, Technologies, Markets and Opportunities Worldwide 2009-2018", Report #D510; MedMarket Diligence, LLC.